%0 Journal Article
%A Haug, Ala Jabri
%A Støer, Nathalie
%A Langseth, Hilde
%A Siafarikas, Franziska
%A Botteri, Edoardo
%A Fortner, Renée Turzanski
%A Lindemann, Kristina
%T Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study.
%J International journal of cancer
%V 157
%N 2
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2025-00436
%P 277-287
%D 2025
%Z Volume157, Issue2, 15 July 2025, Pages 277-287
%X While nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to improve survival in certain cancers, data in patients with endometrial cancer (EC) is conflicting. This study investigated use of aspirin and nonaspirin NSAIDs (NA-NSAIDs) and EC-specific-and all-cause death. This nationwide cohort study linked data from the Cancer Registry of Norway with The Norwegian Prescription database. Patients diagnosed with EC from 2004 to 2018 were included. Post-diagnosis exposure to aspirin and NA-NSAIDs was defined as ≥3 consecutive prescriptions ≥30 days after EC diagnosis, with pre-diagnosis use as ≥2 filled prescriptions <6 months prior to diagnosis. Follow-up started 10 months after diagnosis. Hazard ratios for the risk of death were calculated with multivariable Cox-regression models. Our study population included 7751 individuals with EC, 685 (9
%K NSAIDS (Other)
%K aspirin (Other)
%K endometrial cancer (Other)
%K survival (Other)
%K tertiary prevention (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39992017
%R 10.1002/ijc.35363
%U https://inrepo02.dkfz.de/record/299476